This meta-analysis aims to evaluate the relationships between serum vascular endothelial growth factor (VEGF) level and radiosensitivity in patients with nonsmall cell lung cancer (NSCLC) among Asians. We searched CISCOM, CINAHL, Web of Science, PubMed, Google Scholar, EBSCO, Cochrane Library, and CBM databases from their inception through October 1, 2013. Meta-analysis was performed using the STATA 12.0 software. Fourteen clinical studies were included in this meta-analysis, including five case–control studies and nine cohort studies. Our meta-analysis results revealed that levels of serum VEGF in NSCLC patients were higher than that of healthy controls. There was a significant difference in serum VEGF levels between before and after radiotherapy in NSCLC patients. Further, we found significant differences in serum VEGF levels between effective and noneffective clinical response groups pre- and postradiotherapy. Serum VEGF levels showed no significant associations with tumor–node–metastasis (TNM) stage and histologic grade in NSCLC patients. NSCLC patients with positive VEGF expression had shorter overall survival than those with negative VEGF expression. Our meta-analysis suggests that serum VEGF level may be a useful biomarker in predicting radiosensitivity and prognosis of NSCLC patients among Asians.
Get full access to this article
View all access options for this article.
References
1.
ArinagaM., NoguchiT., TakenoS., ChujoM., MiuraT., and UchidaY. (2003). Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer, 97, 457–464.
2.
AusbornN.L., LeQ.T., BradleyJ.D., ChoyH., DickerA.P., SahaD., et al. (2012). Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys, 83, e453–e464.
3.
BraicuE.I., FotopoulouC., ChekerovR., RichterR., BlohmerJ., KummelS., et al. (2013). Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy. Cytokine, 61, 755–758.
4.
BrattstromD., BergqvistM., HesseliusP., LarssonA., WageniusG., and BrodinO. (2004). Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer, 43, 55–62.
5.
BrayF., JemalA., GreyN., FerlayJ., and FormanD. (2012). Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol, 13, 790–801.
6.
BremnesR.M., CampsC., and SireraR. (2006). Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer, 51, 143–158.
7.
CarmelietP., and JainR.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature, 473, 298–307.
8.
Carrillo-de Santa PauE., Carrillo AriasF., Caso PelaezE., Muguruza TruebaI., Sanchez HernandezI., Munoz MolinaG.M., et al. (2010). Vascular endothelial growth factor (VEGF) serum levels are associated with survival in early stages of lung cancer patients. Cancer Invest, 28, 393–398.
9.
ChoiJ.A., HwangJ.U., YoonY.H., and KohJ.Y. (2013). Methallothionein-3 contributes to vascular endothelial growth factor induction in a mouse model of choroidal neovascularization. Metallomics, 5, 1387–1396.
10.
ChoiJ.H., KimH.C., LimH.Y., NamD.K., KimH.S., YiJ.W., et al. (2001). Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer, 33, 171–179.
11.
D'AndreaL.D., RomanelliA., Di StasiR., and PedoneC. (2010). Bioinorganic aspects of angiogenesis. Dalton Trans, 39, 7625–7636.
12.
de BoerR.H., ArrietaO., YangC.H., GottfriedM., ChanV., RaatsJ., et al. (2011). Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol, 29, 1067–1074.
13.
DengH.B., ZhangX.P., and LiuY. (2005). The study of p53, VEGF, MVD expressions and their correlations in non-small cell lung cancer. Cancer Res Prevent Treatm, 32, 702–704, 741.
14.
DiY., FuZ.Z., GuT., GaoL.M., QiX.M., and YangY.H. (2012). Clinical significance and expression level of VEGF/PLT in serum and Opn before and after chemoradiotherapy in locally advanced non-small cell lung cancer. Chin J Coal Industry Med, 15, 803–805.
15.
EisenhauerE.A., TherasseP., BogaertsJ., SchwartzL.H., SargentD., FordR., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228–247.
16.
FarhatF.S., TfayliA., FakhruddinN., MahfouzR., OtrockZ.K., AlameddineR.S., et al. (2012). Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol, 84, 149–160.
17.
FaurA.C., LazarE., and CornianuM. (2013). Vascular endothelial growth factor (VEGF) expression and microvascular density in salivary gland tumours. APMIS. 1–9.
FormicaV., PalmirottaR., Del MonteG., SavonarolaA., LudoviciG., De MarchisM.L., et al. (2011). Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis, 26, 143–151.
20.
FreemanR., GirshJ., JouA.F., HoJ.A., HugT., DerneddeJ., et al. (2012). Optical aptasensors for the analysis of the vascular endothelial growth factor (VEGF). Anal Chem, 84, 6192–6198.
21.
GengL., DonnellyE., McMahonG., LinP.C., Sierra-RiveraE., OshinkaH., et al. (2001). Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res, 61, 2413–2419.
22.
GuT., FuZ.Z., FuB.H., ZhangL.N., ZhangS.H., and CaoX.Y. (2011). Clinical significance of serum VEGF and TGF-β1 by detecting their expression level before and after three-dimensional conformal radiation therapy in elder patients with non-small cell lung cancer. Chin J Clin Oncol, 38, 1565–1567.
23.
GuX., CunY., LiM., QingY., JinF., ZhongZ., et al. (2013). Human apurinic/apyrimidinic endonuclease siRNA inhibits the angiogenesis induced by X-ray irradiation in lung cancer cells. Int J Med Sci, 10, 870–882.
24.
GuanX., YinM., WeiQ., ZhaoH., LiuZ., WangL.E., et al. (2010). Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10,431.
25.
GuoZ.W., GongY.H., LiY., XueW.C., YanY., and TianQ.H. (2002). Study on changes of vascular endothelial cell growth factor in serum with non small cell hung cancer patients before and after radiotherapy. Chin J Immunol, 18, 807–809.
26.
HeW., TangB., YangD., LiY., SongW., CheangT., et al. (2013). Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients. World J Surg Oncol 11,161.
27.
HicklinD.J., and EllisL.M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23, 1011–1027.
28.
HirakawaS., BrownL.F., KodamaS., PaavonenK., AlitaloK., and DetmarM. (2007). VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood, 109, 1010–1017.
29.
HuangZ.J. (2010). Expression and significance of serum level of vascular endothelial growth factor in patients with non-small cell lung cancer undergoing radiotherapy. J Pract Med, 26, 2503–2505.
30.
IwasakiA., KuwaharaM., YoshinagaY., and ShirakusaT. (2004). Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg, 25, 443–448.
31.
JiX., WangZ., SarkarF.H., and GuptaS.V. (2012). Delta-tocotrienol augments cisplatin-induced suppression of non-small cell lung cancer cells via inhibition of the Notch-1 pathway. Anticancer Res, 32, 2647–2655.
32.
JonesR.G., and ThompsonC.B. (2009). Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev, 23, 537–548.
33.
KawaiH., MinamiyaY., ItoM., SaitoH., and OgawaJ. (2008). VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients. Lung Cancer, 59, 41–47.
34.
KayaA., CiledagA., GulbayB.E., PoyrazB.M., CelikG., SenE., et al. (2004). The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med, 98, 632–636.
35.
KimS.W., KimM.Y., LeeY.P., RyuY.J., LeeS.J., LeeJ.H., et al. (2013). Clinical features and prognostic factors in elderly koreans with advanced non-small-cell lung cancer in a tertiary referral hospital. Tuberc Respir Dis (Seoul), 75, 52–58.
36.
LimE.H., ZhangS.L., LiJ.L., YapW.S., HoweT.C., TanB.P., et al. (2009). Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol, 4, 12–21.
37.
LinderholmB., TavelinB., GrankvistK., and HenrikssonR. (1999). Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?. Br J Cancer, 81, 727–732.
38.
LittleJ., HigginsJ.P., IoannidisJ.P., MoherD., GagnonF., von ElmE., et al. (2009). Strengthening the reporting of genetic association studies (STREGA)—an extension of the STROBE statement. Eur J Clin Invest, 39, 247–266.
39.
LoncasterJ.A., CooperR.A., LogueJ.P., DavidsonS.E., HunterR.D., and WestC.M. (2000). Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer, 83, 620–625.
40.
MaH., BoY.J., LiN., YangW.B., and ZhangT.Y. (2010). Significance of combined determination of vascular endothelial growth factor, CA125 and carcinoembryanic antigen in peripheral blood of patients with non-small cell lung cancer. Chongqing Med J, 39, 430–431, 433.
41.
MaekawaS., IwasakiA., ShirakusaT., EnatsuS., KawakamiT., and KurokiM. (2007). Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res, 27, 3735–3741.
42.
MengL., ZhangY.D., and WangY.B. (2010). Clinical significance of vascular endothelial growth factor C and CD44v6 expressions in hunam non-small cell lung cancer. J Shandong Univers (Health Science), 48, 83–86.
43.
MolinaJ.R., YangP., CassiviS.D., SchildS.E., and AdjeiA.A. (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584–594.
44.
Naga DeepthiC. (2011). Role of tumor suppressor protein p53 in apoptosis and cancer therapy. J Cancer Sci Ther, S17, 001.
45.
NaumnikW., NilklinskaW., OssolinskaM., and ChyczewskaE. (2009). Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol, 47, 703–709.
46.
NiersT.M., RichelD.J., MeijersJ.C., and SchlingemannR.O. (2011). Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One 6,e19873.
47.
PetersJ.L., SuttonA.J., JonesD.R., AbramsK.R., and RushtonL. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676–680.
48.
RadesD., SetterC., DunstJ., DahlO., SchildS.E., and NoackF. (2010). Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC). Strahlenther Onkol, 186, 307–314.
49.
SaharinenP., EklundL., PulkkiK., BonoP., and AlitaloK. (2011). VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med, 17, 347–362.
50.
SalgiaR. (2011). Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer, 117, 3889–3899.
51.
SanoD., MatsumotoF., ValdecanasD.R., ZhaoM., MolkentineD.P., TakahashiY., et al. (2011). Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res, 17, 1815–1827.
52.
SengerD.R. (2010). Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell, 21, 377–379.
53.
ShintaniY., OkimuraA., SatoK., NakagiriT., KadotaY., InoueM., et al. (2011). Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg, 92, 1794–1804.
54.
SinaK., SoniaT., XiujuanL., LauraG., and LenaC.-W. (2011). Signal transduction by vascular endothelial growth factor receptors. Biochem J, 437, 169–183.
55.
SteffensenK.D., WaldstromM., BrandslundI., and JakobsenA. (2010). The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol, 117, 109–116.
56.
TakahashiS. (2011). Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull, 34, 1785–1788.
57.
ThangarajahH., YaoD., ChangE.I., ShiY., JazayeriL., VialI.N., et al. (2009). The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A, 106, 13505–13510.
58.
TischlerV., PfeiferM., HausladenS., SchirmerU., BondeA.-K., KristiansenG., et al. (2011). L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer 10,127.
59.
ToiM., MatsumotoT., and BandoH. (2001). Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol, 2, 667–673.
60.
TopkanE., ParlakC., TopukS., GulerO.C., and SelekU. (2013). Outcomes of aggressive concurrent radiochemotherapy in highly selected septuagenarians with stage IIIB non-small cell lung carcinoma: retrospective analysis of 89 patients. Lung Cancer, 81, 226–230.
61.
TsutsuiS., MatsuyamaA., YamamotoM., TakeuchiH., OshiroY., IshidaT., et al. (2010). The Akt expression correlates with the VEGF-A and -C expression as well as the microvessel and lymphatic vessel density in breast cancer. Oncol Rep, 23, 621–630.
62.
VeeravaguA., HsuA.R., CaiW., HouL.C., TseV.C., and ChenX. (2007). Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov, 2, 59–71.
63.
WangH.B., LinY.C., LinW.Z., ZengD., LinW., and HongC.Q. (2008). Clinical significance of serum vascular endothelial growth factor in advanced malignant tumors. Chin Clin Oncol, 13, 126–128.
64.
WangR.H., XieJ.G., ChenH., RenT.T., and ZhangY.C. (2013). Expression of angiopoietin-2 and vascular endothelial growth factor in human colon cancer. Nan Fang Yi Ke Da Xue Xue Bao, 33, 1236–1239.
65.
WangY.P., WangM.Z., LuoY.R., WeiZ.X., and XuanY.P. (2012). Clinical study of vaecular endothelial frowth factor-C and cytokeratin 19 in stage I non-small cell lung cancer patients. Chin J Clin Thorac Cardiovasc Surg, 19, 385–389.
66.
WeisS.M., and ChereshD.A. (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med, 17, 1359–1370.
67.
YangS.Y., ZhongZ.P., HuL.J., WangJ.J., CaiP., and ShiD.P. (2011). A clinical analysis of the whole body therm aerotherapy for patients with nin-small cell lung cancer after operation. Chin J Clin Oncol Rehabilit, 18, 66–68.
68.
YilmazA., ErnamD., UnsalE., DemiragF., AtikcanS., and TastepeI. (2007). Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res, 38, 764–768.
69.
YinM., LiaoZ., YuanX., GuanX., O'ReillyM.S., WelshJ., et al. (2012). Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci, 103, 945–950.
70.
ZhangH.J., GuoW.D., NiuD.S., DiJ.J., LiH.L., GengC.L., et al. (2010). Observation on efficacy of radiotherapy combined with hyperthermia in treatment of non-small cell lung cancer and significance of change of VEGF, sIL-2R and IL-6. Chin J Clin Oncol Rehabilit, 17, 299–304.
71.
ZhangS., HuL.K., XuM., FuL., and ZhuX.L. (2008). Significance of serum vascular endothelial growth factor in non-small cell lung cancer. J Shandong Uni (Health Sciences), 46, 1177–1180.
72.
ZhangW.C., Shyh-ChangN., YangH., RaiA., UmashankarS., MaS., et al. (2012a). Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell, 148, 259–272.
73.
ZhangY., YuL.K., and XiaN. (2012b). Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion. Asian Pac J Trop Med, 5, 239–242.
74.
ZhaoX.F., LiuX.Q., GuoW.F., and LiX.B. (2010). Expression of carbonic anhydrase IX in NSCLC and its Relationship with VEGF and Ki67 expression. Chin J Lung Cancer, 13, 861–866.
75.
ZhouW.B., BaiM., and JinY. (2009). Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tuberc Lung Dis, 13, 381–386.
76.
ZintzarasE., and IoannidisJ.P. (2005). HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics, 21, 3672–3673.
